explore -WSS

explore

author：focus 2025-08-23 08:56:34 - browse：52792

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Did you have Obamacare on your GOP debate bingo card?

WSS

Mindstrong's demise and the future of mental health care

What would happen to your eyes if you looked at the solar eclipse?

Cloning humans is technically possible. It's curious no one has tried

Kaiser Permanente unions announce official strike date

Cloning humans is technically possible. It's curious no one has tried

Ionis has late

focus

explore

focus

Novavax promises a turnaround & Lilly roils the obesity market

Address the ethical violations that led to 'Three Identical Strangers'

Moonlake's readout produced a cash windfall. Risks remain

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Medicare details structure of new drug price negotiation program

3 hurdles to bringing medical devices to the U.S. market

In Memoriam: Notable people who died in 2023

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

As demand for Covid shots wanes, Moderna seeks its next success

Would Medicare drug price negotiations stall in a shutdown?

Wikipedia

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Donald Trump's relentless attacks on special counsel Jack Smith

Biogen shutters digital health group, ends Apple study, in cost cutting move

Medicare drug price negotiation program allowed for now

With FDA staff opposed to Sarepta therapy, top official intervened

How one patient went off dialysis — and others can too

leisure time

focus

hotspot

knowledge